A growing number of clinicians rely on AdaptDx to detect age-related macular degeneration in their adult patients. Our customers tell the story of how they’re fighting against blindness caused by AMD.
The AdaptDx is simple for the patient and takes little staff training to become proficient at administering. Analyzing the data by the doctor only takes seconds and is very simple to interpret. This allows more time to discuss with the patient the results and the plan of action when needed.
The test is a great benchmark that I use to determine depth of the disease and how soon the patient needs to return for another visit.
I’ve had fellow practitioners that have said, ‘I didn’t know this was out here’ about the AdaptDx. But once you see the science behind the device, you realize what it can do for your practice and AMD patients. It becomes clear how much easier it is to detect AMD earlier and to track its progression. We as Vision Source doctors tend to practice more comprehensive eye care over just refractions and this becomes increasingly effortless with the AdaptDx dark adaptometer.
Thanks to the comprehensive AMD Excellence training program from MacuLogix, each staff member - from the front desk and optical to technicians and billing - understands the important role they play in AMD care.
The impact of the AdaptDx on my patient care and practice revenue has been phenomenal!
AdaptDx more than paid for itself within the first few months.
Equipment companies usually ship you a big box and you never hear from them again. That was not the case with MacuLogix and their AdaptDx. They spent 2 days with us and did a fantastic job training our whole office!
Our doctors decided that we should be doing an AMD screening for our patients over the age of 65 no matter what. Photos and looking at the macula is just not enough. If you look at the statistics, it makes more sense to do an AdaptDx test on this population than it does to take a tonometry reading to screen for glaucoma!! We decided we wanted to be more proactive and take better care of our patients. Using the AdaptDx to find subclinical AMD enables us to do just that.
I strongly believe that if we can catch AMD at a very early stage and be really proactive with recommending supplements, blue light filters, sunglasses, telling them to watch their BMI, their cholesterol levels, that we can stop or slow this down and maintain their vision the rest of their life.
One of the great things about the AdaptDx is that it’s a very straightforward test to understand as a practitioner. It’s basically a yes-or-no test. If somebody has impaired dark adaptation, which means their ability to recover from a bright light takes longer than 6.5 minutes, we know with 90% sensitivity and specificity that the patient has macular degeneration.